Epclusa is first kind drug approved by US FDA for the treatment of all six major HCV genotypes. Epclusa contains combination of sofosbuvir, a drug approved by FDA as break through therapy for HCV and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.
US FDA approved this drug on July 28 2016 for the treatment of chronic type of hepatitis in adult patients with cirrhosis or without cirrhosis. If liver cirrhosis progresses to advance stage then Epclusa is used with antiviral drug called as ribavirin.
Hepatitis C is a viral infection leads towards liver cirrhosis if it persists for a long term. HCV virus has 6 genotypes 1 to 6. Each genotype requires duration of therapy and in some cases therapy may also be changed. In United States about 75% people have genotype 1 that means genotype 1 is the most common type in United States of America. Genotype 2 has prevalence rate of 25%. Other genotypes are less common and only few patients are diagnosed with such kind of genotypes.
|Epclusa Cost, Side effects, Dosage, Uses for Hepatitis C infection|
Epclusa Side effects
There are two types of side effects that were observed during Epclusa clinical trials like moderate and severe type of side effects.
Moderate Side effects include
- Dry Cough
- Stomach discomfort
- Cardiac arrhythmia
Epclusa Uses or Prescribing Information
Epclusa is prescribed for the treatment of chronic HCV infection in adults having liver cirrhosis or do not have liver cirrhosis. It indicated for all kinds of HCV genotypes because it contains combination of drugs. Up-till now, Epclusa is only regimen to treat all six major HCV genotypes effectively.